Choate Investment Advisors reduced its stake in Kronos Bio, Inc. (NASDAQ:KRON – Free Report) by 11.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 274,787 shares of the company’s stock after selling 33,910 shares during the quarter. Choate Investment Advisors owned about 0.46% of Kronos Bio worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Peapod Lane Capital LLC purchased a new stake in Kronos Bio in the fourth quarter valued at approximately $534,000. 64.09% of the stock is owned by institutional investors.
Kronos Bio Price Performance
Shares of KRON opened at $0.95 on Tuesday. The firm’s 50 day simple moving average is $0.98 and its 200 day simple moving average is $0.96. The company has a market capitalization of $57.32 million, a P/E ratio of -0.66 and a beta of 1.79. Kronos Bio, Inc. has a 1-year low of $0.69 and a 1-year high of $1.60.
About Kronos Bio
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Read More
- Five stocks we like better than Kronos Bio
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Can TikTok Stock Picks Really Make You Rich?
- Do ETFs Pay Dividends? What You Need to Know
- The “Quality” Rotation: Back to Basics Investing
- Health Care Stocks Explained: Why You Might Want to Invest
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.